You are here

Heart Failure

 

Coronary artery bypass grafting (CABG) is preferred to percutaneous coronary intervention for patients with diabetes and coronary artery disease (CAD). But new research showed CABG outperformed PCI when focusing specifically on individuals with left ventricular dysfunction (LVD), a population that had been excluded in past studies.

The FDA has expanded its premarket approval for Impella heart pumps to include treatment for heart failure associated with cardiomyopathy leading to cardiogenic shock, device manufacturer Abiomed announced Feb. 13.

Exposure to noise pollution has been shown to negatively impact cardiovascular health. But researchers have only recently begun to explore exactly how noise can harm health. A study published online Feb. 6 in the Journal of the American College of Cardiology explored the connection between noise and arterial hypertension, myocardial infarction, heart failure and stroke.

Aspirin is ineffective in preventing heart attack, stroke and death in heart failure patients without atrial fibrillation (AFib), according to a nationwide study in Denmark. In fact, patients on aspirin may be more likely to have myocardial infarction (MI) or be rehospitalized for heart failure, Christian Madelaire, MD, and colleagues reported in JACC: Heart Failure.

Certain breast cancer therapies, including popular HER-2 targeted treatments, could be harmful to the heart in patients already at an increased risk for cardiovascular disease (CVD), the American Heart Association reported this week in a new scientific statement.

 

Recent Headlines

ACC: Heart failure model could predict outcomes for patients, shorten inpatient stays ATLANTA--In utilizing the Seattle Heart Failure Model (SHFM), overall survival scores for patients admitted with acutely decompensated heart failure (ADHF) may be improved, according to Samira Bahrainy, MD, department of cardiology at the University of Washington, Harborview Medical Center, and colleagues during the poster presentations held on March 15 at the 59th annual American College of Cardiology (ACC) conference.
Heart Failure Treatments Widen with Continuous-Flow Assist Devices Now that continuous-flow left ventricular assist devices (LVAD) are available as a destination therapy, rather than just a bridge-to-transplant therapy, options for late-stage heart failure patients have expanded. The new indication is welcome news, but the debate has begun regarding which patients are the best candidates, and when in their care cycle to implant LVADs.
Abbott's obesity drug contraindicated for heart patients The FDA has warned that a review of additional data indicates an increased risk of heart attack and stroke in patients with a history of cardiovascular disease using sibutramine (Meridia, Abbott Laboratories), a drug used to curb obesity and enhance weight loss.
AHJ: Most eligible patients miss out on CRT for heart failure Most patients with heart failure likely to benefit from a pacemaker including with the capacity for cardiac resynchronization therapy (CRT) do not receive such an implantable device, according to a study in the December issue of the American Heart Journal.
NEJM: Newer LVADs surpass older devices for heart failure Advanced heart failure patients treated via a continuous-flow left ventricular assist device (LVAD) showed increased survival rates and a decrease in adverse events and device replacements compared to those treated with pulsatile-flow LVADs, a trial published Nov. 17 in the New England Journal of Medicine found.
AHA: Load up on ARBs for fewer heart failure hospital admissions Orlando, Fla.Using a higher dose of the angiotensin-receptor blocker (ARB) losartan reduces death or hospital admission for heart failure, based on the findings of the HEAAL study, presented Tuesday at the American Heart Association conference.
Heart Failure Management Hinges on Care Collaboration

With increasing numbers of Americans affected by heart failure, the healthcare systems mantra for care is teamwork.

NEJM: ICD does not improve death risk after heart attack
Prophylactic implantable cardioverter-defibrillator (ICD) therapy did not reduce overall mortality among patients with acute MI and clinical features that placed them at increased risk, according to the randomized, prospective IRIS trial published Thursday in the New England Journal of Medicine.
AJC: Abdominal obesity linked with heart failure hospitalization, CV events Abdominal obesity is an independent predictor of heart failure hospitalization and recurrent cardiovascular events in patients with stable coronary heart disease, according to the prospective cohort Heart and Soul Study published Oct. 1 in the American Journal of Cardiology.
JACC: Only half of eligible patients getting mitral valve surgery Overblown fears about surgical risk and lack of awareness about the risk of not operating are among the reasons only half of eligible patients were referred for mitral valve repair, according to a study in the Aug. 25 issue of the Journal of the American College of Cardiology.

Pages